MedPath

Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Phase 4
Active, not recruiting
Conditions
Arteriosclerosis
Myocardial Ischemia
Heart Diseases
Acute Coronary Syndrome
Arterial Occlusive Diseases
Coronary Artery Disease
Syndrome Heart Disease
Cardiovascular Diseases
Coronary Disease
Vascular Diseases
Interventions
Registration Number
NCT04624854
Lead Sponsor
Harbin Medical University
Brief Summary

This study is a prospective, multicenter, parallel, open-label, randomized, controlled, superiority trial. It is planned to recruit 8,250 patients with multi-vessel disease(MVD), and the patients will be followed-up for at least 12 months after being implanted with a drug-eluting stent (DES) at one of 100 different centers. All patients will be randomly divided into the treatment group and control group on a 1:1 basis, based on a complete randomization.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
8250
Inclusion Criteria
  • The enrolled subjects must meet all of the following criteria:

    1. Aged 18-75 years old (inclusive).
    2. Patients with MVD who underwent DES implantation for 12 months.
    3. Patients have been treated with aspirin and can tolerant of aspirin at doses of 75-150 mg/day as maintenance therapy during the study period.
    4. Patients have signed informed consent.
Exclusion Criteria
  • Subjects who meet any one of the following criteria are excluded from the study:
  1. Planned to use of ADP receptor blockers (eg, clopidogrel, ticagrelor, and ticlopidine), dipyridamole, or cilostazol.

  2. Contraindication to ADP receptor blockers or aspirin.

  3. Planned to use anticoagulants during the study period.

  4. Planned coronary, cerebrovascular, or peripheral arterial revascularization during the study period.

  5. Planned major cardiac or non-cardiac surgery during the study period.

  6. Concomitant oral or intravenous therapy with CYP2C19 medium or strong inhibitors.

  7. Known severe liver disease(ALT/AST is 3 times above normal).

  8. Subjects with renal failure who required or anticipated dialysis during the study period.

  9. Platelet count <50×10^9/L.

  10. Patients with:

    • A history of intracranial bleed or ischemic stroke at any time.
    • A central nervous system tumor or intracranial vascular abnormality (eg, aneurysm, arteriovenous malformation) at any time.
    • Intracranial or spinal cord surgery within 5 years.
  11. Pregnancy or lactation or planned to pregnant during the study period.

  12. Life expectancy < 1 year.

  13. Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study (eg, active malignancy other than squamous cell or basal cell skin cancer).

  14. Concern for inability of the patient to comply with study procedures and/or followup (eg, alcohol or drug abuse).

  15. Participation in another clinical study and did not reach the major endpoint.

  16. Involvement in the planning and/or conduct of the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Aspirin monotherapyAspirin monotherapyPatients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
Clopidogrel and Aspirin dual-antiplatelet therapyClopidogrel and Aspirin dual-antiplatelet therapyPatients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
Primary Outcome Measures
NameTimeMethod
Incidence of MACCE(cardiovascular death, nonfatal myocardial infarction or nonfatal stroke).Through study completion, an average of 2 years.

To evaluate the effect of Clopidogrel and Aspirin dual-antiplatelet therapy on the incidence of MACCE in patients with MVD

Secondary Outcome Measures
NameTimeMethod
Incidence of emergency revascularization.Through study completion, an average of 2 years.

To evaluate the effect of Clopidogrel and Aspirin dual-antiplatelet therapy on the incidence of emergency revascularization in patients with MVD.

Incidence of repeat revascularization.Through study completion, an average of 2 years.

To evaluate the effect of Clopidogrel and Aspirin dual-antiplatelet therapy on the incidence of any repeat revascularization in patients with MVD.

Incidence of all-cause mortality.Through study completion, an average of 2 years.

To evaluate the effect of Clopidogrel and Aspirin dual-antiplatelet therapy on the incidence of all-cause mortality in patients with MVD.

Incidence of cardiovascular death.Through study completion, an average of 2 years.

To evaluate the effect of Clopidogrel and Aspirin dual-antiplatelet therapy on the incidence of cardiovascular death in patients with MVD.

Incidence of nonfatal myocardial infarction.Through study completion, an average of 2 years.

To evaluate the effect of Clopidogrel and Aspirin dual-antiplatelet therapy on the incidence of nonfatal myocardial infarction in patients with MVD.

Incidence of cardiovascular death or hospitalization.Through study completion, an average of 2 years.

To evaluate the effect of Clopidogrel and Aspirin dual-antiplatelet therapy on the incidence of cardiovascular death or hospitalization (myocardial infarction, stroke, emergency revascularization, unstable angina or TIA) caused by thrombotic events in patients with MVD.

Incidence of nonfatal stroke.Through study completion, an average of 2 years.

To evaluate the effect of Clopidogrel and Aspirin dual-antiplatelet therapy on the incidence of nonfatal stroke in patients with MVD.

Incidence of clinical adverse events.Through study completion, an average of 2 years.

To evaluate the effect of Clopidogrel and Aspirin dual-antiplatelet therapy on the incidence of clinical adverse events (MACCE and BARC defined as type 2-5) in patients with MVD.

Incidence of definite/possible stent thrombosis.Through study completion, an average of 2 years.

To evaluate the effect of Clopidogrel and Aspirin dual-antiplatelet therapy on the incidence of definite/possible stent thrombosis in patients with MVD.

Trial Locations

Locations (110)

Hezhou People's Hospital

🇨🇳

Hezuo, Guangxi, China

The Second Affiliated Hospital of Army Medical University

🇨🇳

Chongqing, Chongqing, China

Xiamen Fifth Hospital

🇨🇳

Xiamen, Fujian, China

Pingquan County Hospital

🇨🇳

Qingyang, Gansu, China

Daqing Oilfield General Hospital

🇨🇳

Daqing, Heilongjiang, China

Harbin Second Hospital

🇨🇳

Harbin, Heilongjiang, China

The First Affiliated Hospital of Chongqing Medical University

🇨🇳

Chongqing, Chongqing, China

Mishan People's Hospital

🇨🇳

Mishan, Heilongjiang, China

Mudanjiang City Second People's Hospital

🇨🇳

Mudanjiang, Heilongjiang, China

Hongqi Hospital of Mudanjiang Medical University

🇨🇳

Mudanjiang, Heilongjiang, China

Mudanjiang Cardiovascular Hospital

🇨🇳

Mudanjiang, Heilongjiang, China

Mudanjiang Administration Center Hospital of Heilongjiang Land Reclamation

🇨🇳

Mudanjiang, Heilongjiang, China

Mudanjiang First People's Hospital

🇨🇳

Mudanjiang, Heilongjiang, China

The Third Affiliated Hospital of Qiqihar Medical University

🇨🇳

Qiqihar, Heilongjiang, China

The First Affiliated Hospital of Qiqihar Medical University

🇨🇳

Qiqihar, Heilongjiang, China

Shuangyashan People's Hospital

🇨🇳

Shuangyashan, Heilongjiang, China

The People's Hospital of Baoqing

🇨🇳

Shuangyashan, Heilongjiang, China

Suihua First Hospital

🇨🇳

Suihua, Heilongjiang, China

Hongxinglong Central Hospital

🇨🇳

Shuangyashan, Heilongjiang, China

Daxing'anling Prefecture People's Hospital

🇨🇳

Xing'anling, Heilongjiang, China

Tieli People's Hospital

🇨🇳

Yichun, Heilongjiang, China

Yichun First Hospital

🇨🇳

Yichun, Heilongjiang, China

The First Affiliated Hospital of Nanyang Medical College

🇨🇳

Nanyang, Henan, China

Puyang People's Hospital

🇨🇳

Puyang, Henan, China

The First People's Hospital of Shangqiu

🇨🇳

Shangqiu, Henan, China

Central Hospital of Yongcheng

🇨🇳

Shangqiu, Henan, China

The Seventh People's Hospital of Zhengzhou

🇨🇳

Zhengzhou, Henan, China

The Fourth Hospital of Wuhan

🇨🇳

Wuhan, Hubei, China

Dancheng People's Hospital

🇨🇳

Zhoukou, Henan, China

Zhongnan Hospital of Wuhan University

🇨🇳

Wuhan, Hubei, China

The Third Xiangya Hospital of Central South University

🇨🇳

Changsha, Hunan, China

The First Affiliated Hospital of University of South China

🇨🇳

Hengyang, Hunan, China

The First People's Hospital of Lianyungang

🇨🇳

Lianyungang, Jiangsu, China

First People's Hospital of Fuzhou

🇨🇳

Fuzhou, Jiangxi, China

The Second Affiliated Hospital of Jilin University

🇨🇳

Chang chun, Jilin, China

Affiliated Hospital of Changchun Traditional Chinese Medicine University

🇨🇳

Changchun, Jilin, China

The First Affiliated Hospital of Jilin University

🇨🇳

Changchun, Jilin, China

Jilin Integrated Traditional Chinese and Western Medicine Hospital

🇨🇳

Jilin, Jilin, China

General Hospital of Jihua Group Company

🇨🇳

Jilin, Jilin, China

The First Affiliated Hospital of Dalian Medical University

🇨🇳

Dalian, Liaoning, China

Hulunbeir People's Hospital

🇨🇳

Hulunbeir, Neimeng, China

Feicheng Hospital of Shandong Guoxin Yiyang Group

🇨🇳

Fengcheng, Shandong, China

The Fifth People's Hospital of Jinan

🇨🇳

Jinan, Shandong, China

General Hospital of Ningxia Medical University

🇨🇳

Yinchuan, Ningxia, China

Shandong Second Provincial General Hospital

🇨🇳

Jinan, Shandong, China

Yanzhou District People's Hospital

🇨🇳

Jining, Shandong, China

Taian City Central Hospital

🇨🇳

Tai'an, Shandong, China

Wusong hospital Affiliated Zhongshan Hospital of Fudan University

🇨🇳

Shanghai, Shanghai, China

Tianjin Medical University General Hospital

🇨🇳

Tianjin, Tianjin, China

Xinjiang Uiger Municipal People's Hospital

🇨🇳

Ürümqi, Xinjiang, China

The First Affiliated Hospital, Sun Yat-Sen University

🇨🇳

Guangzhou, Guangdong, China

Affiliated Hospital of Zunyi Medical University

🇨🇳

Zunyi, Guizhou, China

Haikou People's Hospital

🇨🇳

Haikou, Hainan, China

Affiliated Beijing Luhe Hospital of Capital Medical University

🇨🇳

Beijing, Beijing, China

Fujian Provincial Hospital

🇨🇳

Fuzhou, Fujian, China

Shenzhen People's Hospital

🇨🇳

Shenzhen, Guangdong, China

Guangdong Provincial People's Hospital

🇨🇳

Zhongshan, Guangdong, China

The Eighth Affiliated Hospital, Sun Yat-Sen University

🇨🇳

Zhongshan, Guangdong, China

Hainan General Hospital

🇨🇳

Haikou, Hainan, China

The Second Affiliated Hospital of Hainan Medical University

🇨🇳

Haikou, Hainan, China

Cangzhou Central Hospital

🇨🇳

Cangzhou, Hebei, China

Affiliated Hospital of Chengde Medical University

🇨🇳

Chengde, Hebei, China

Harrison International Peace Hospital

🇨🇳

Hengshui, Hebei, China

The Second Hospital of Hebei Medical University

🇨🇳

Shijiazhuang, Hebei, China

The Third Hospital of Shijiazhuang

🇨🇳

Shijiazhuang, Hebei, China

Tangshan Central Hospital

🇨🇳

Tangshan, Hebei, China

The Second Affiliated Hospital of Xingtai Medical College

🇨🇳

Xingtai, Hebei, China

Xingtai Third Hospital

🇨🇳

Xingtai, Hebei, China

Daqing Long Nan Hospital

🇨🇳

Daqing, Heilongjiang, China

Daqing People's Hosipital

🇨🇳

Daqing, Heilongjiang, China

The Fourth Affiliated Hospital of Harbin Medical University

🇨🇳

Harbin, Heilongjiang, China

Harbin First Hospital

🇨🇳

Harbin, Heilongjiang, China

Heilongjiang Province Hospital

🇨🇳

Harbin, Heilongjiang, China

Harbin 242 Hospital

🇨🇳

Harbin, Heilongjiang, China

The Second Affiliated Hospital of Harbin Medical University

🇨🇳

Harbin, Heilongjiang, China

The Second Cancer Hospital of Heilongjiang Province

🇨🇳

Harbin, Heilongjiang, China

Shuangcheng People's Hospital

🇨🇳

Harbin, Heilongjiang, China

Hegang Mining Group General Hospital

🇨🇳

Hegang, Heilongjiang, China

Hegang People's Hospital

🇨🇳

Hegang, Heilongjiang, China

Heilongjiang Provincial Agricultural Reclamation Baoquanling Administration Center Hospital

🇨🇳

Hegang, Heilongjiang, China

Nenjiang People's Hospital

🇨🇳

Heihe, Heilongjiang, China

The Central Hospital of Jiamusi City

🇨🇳

Jiamusi, Heilongjiang, China

The First Affiliated Hospital of Jamusi University

🇨🇳

Jiamusi, Heilongjiang, China

The Jiansanjiang People's Hospital of Heilongjiang Land Reclamation

🇨🇳

Jiamusi, Heilongjiang, China

Jixi Jikuang Hospital

🇨🇳

Jixi, Heilongjiang, China

Jixi People's Hospital

🇨🇳

Jixi, Heilongjiang, China

Qiqihar Jianhua Hospital

🇨🇳

Qiqihar, Heilongjiang, China

Emergency General Hospital of Shuangyashan

🇨🇳

Shuangyashan, Heilongjiang, China

Yichun Forestry Central Hospital

🇨🇳

Yichun, Heilongjiang, China

Kaifeng Central Hospital

🇨🇳

Kaifeng, Henan, China

Nanyang First People's Hospital

🇨🇳

Nanyang, Henan, China

The Second People's Hospital of Xinxiang City

🇨🇳

Xinxiang, Henan, China

Yongcheng People's Hospital

🇨🇳

Yongcheng, Henan, China

The First Affiliated Hospital of Zhengzhou University

🇨🇳

Zhengzhou, Henan, China

Yichang First People's Hospital

🇨🇳

Yichang, Hubei, China

Renmin Hospital of Wuhan University

🇨🇳

Wuhan, Hubei, China

Zhongda Hospital Southeast University

🇨🇳

Nanjing, Jiangsu, China

Pizhou People's Hospital

🇨🇳

Pizhou, Jiangsu, China

The Third Affiliated Hospital of Jilin University

🇨🇳

Chang chun, Jilin, China

Jilin Central Hospital

🇨🇳

Jilin, Jilin, China

Songyuan Central Hospital

🇨🇳

Songyuan, Jilin, China

Dalian Municipal Cental Hospital

🇨🇳

Dalian, Liaoning, China

Inner Mongolia People's Hospital

🇨🇳

Neimeng, Neimeng, China

Tianjin Chest Hospital

🇨🇳

Tianjin, Tianjin, China

Shanxi Provincial People's Hospital

🇨🇳

Xian, Shanxi, China

Dazhou Central Hospital

🇨🇳

Dazhou, Sichuan, China

The Fourth People's Hospital of Jinan

🇨🇳

Jinan, Shandong, China

Qilu Hospital of Shandong University

🇨🇳

Jinan, Shandong, China

The Second People's Hospital of Liaocheng

🇨🇳

Liaocheng, Shandong, China

The First Affiliated Hospital of Xinjiang Medical University

🇨🇳

Ürümqi, Xinjiang, China

© Copyright 2025. All Rights Reserved by MedPath